uterine corpus cancer: A uterine cancer that is located_in the uterine corpus.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
159 |
4. Check minimum number of eventsNone |
159 |
5. Include endpointsNone |
159 |
6. Filter based on genotype QC (FinnGen only) |
159 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D10
- Name in latin
- Neoplasma benignum hypopharyngis
Similar endpoints
↥List of similar endpoints to
Benign neoplasm: Hypopharynx
based on the number of shared cases.
Similar with more cases:
- Benign neoplasm: Hypopharynx
- Benign neoplasm of mouth and pharynx
- Benign neoplasm of mouth and pharynx
- Benign neoplasms
- Benign neoplasms
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 787 | 363 | 414 |
| Only index persons | 644 | 303 | 341 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 59.62 | 57.19 | 61.60 |
| Only index persons | 59.07 | 56.24 | 61.58 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 159 | 61 | 98 |
| Unadjusted period prevalence (%) | 0.03 | 0.02 | 0.04 |
| Median age at first event (years) | 58.38 | 49.61 | 63.83 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 140
- Matched controls
- 1401
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D10.7
ICD-10 Finland
Benign neoplasm: Hypopharynx
+∞
155.9
119
*
UJC01
NOMESCO Finland
Scopy of lower throat
99.8
44.4
47
7
JDB10
NOMESCO Finland
Percutaneous gastrostomy
49.4
23.7
28
7
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
40.1
23.5
29
9
C13.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of hypopharynx
+∞
17.0
16
*
2108A
ICD-9 Finland
Benign neoplasm of lip, oral cavity and pharynx, Hypopharynx
+∞
17.0
16
*
UDQ12
NOMESCO Finland
Flexible laryngoscopy
10.9
15.5
30
34
D14.1
ICD-10 Finland
Benign neoplasm: Larynx
38.3
13.9
17
5
WF002
NOMESCO Finland
Radical radiotherapy
9.9
13.3
27
33
130
Kela drug reimbursment
Malignant tumour
7.2
13.2
33
57
UDQ22
NOMESCO Finland
Microlaryngoscopy
35.8
12.9
16
5
DQB10
NOMESCO Finland
Endoscopic excision of lesion of larynx
17.0
11.7
18
12
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
6.1
11.0
31
62
8070/3-C13.9
ICD-O-3
Squamous cell carcinoma, NOS, of hypopharynx, NOS
118.5
10.6
11
*
EN1BD
NOMESCO Finland
Very extensive CT examination of mouth and soft tissues of neck
20.8
10.5
15
8
WX408
NOMESCO Finland
General anesthesy, balanced
3.5
10.2
60
247
C12
ICD-10 Finland
Malignant neoplasm of piriform sinus
+∞
9.5
9
*
R07.0
ICD-10 Finland
Pain in throat
7.8
9.3
21
31
GBB00
NOMESCO Finland
Tracheostomy
17.1
9.2
14
9
ZXC10
NOMESCO Finland
Use of laser
13.8
9.1
15
12
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
29.6
8.6
11
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
10.3
8.0
15
16
R13
ICD-10 Finland
Dysphagia
6.1
7.9
21
39
ENA10
NOMESCO Finland
Biopsy of pharynx
47.7
7.8
9
*
R4190
NOMESCO Finland
Nutritional therapy
9.7
7.8
15
17
EP1AE
NOMESCO Finland
Neck ultrasound examination
6.3
7.7
20
36
EP1DG
NOMESCO Finland
Very extensive examination of soft tissue of neck with high intesity magnet
84.4
7.5
8
*
QA1S1
NOMESCO Finland
Photography of skin or subcutaneous tissue in head
+∞
7.3
7
*
D38.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Larynx
21.4
7.2
10
5
UJC02
NOMESCO Finland
Rigid oesophagoscopy
23.9
6.8
9
*
K04.5
ICD-10 Finland
Chronic apical periodontitis
2.7
6.4
51
243
WX402
NOMESCO Finland
General anaesthesia
3.3
6.3
34
124
ENB00
NOMESCO Finland
Excision or exploration of lesion of pharynx
+∞
6.3
6
*
A02BC05
ATC
esomeprazole; systemic
2.5
6.2
70
402
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
4.9
6.1
19
43
WZC10
NOMESCO Finland
Extensive specialist consultion with written report
5.9
6.1
16
30
N02AA05
ATC
oxycodone; systemic
3.2
6.0
33
123
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
103
632
2.79
8.74
10.8
6.7
1.2
1.2
mmol/l
1.17
94
544
53
232
2.93
8.67
2.8
2.7
1.1
0.9
e6/l
0.13
29
134
84
489
2.52
7.58
4.4
3.1
—
—
—
0
0
70
375
2.55
7.54
3.8
3.1
0.4
0.5
e6/l
0.00
58
287
49
220
2.77
7.53
3.0
2.9
2.1
1.9
e6/l
0.09
25
124
113
763
2.66
7.34
13.9
10.0
4.2
4.0
e9/l
0.51
105
666
90
559
2.41
6.82
7.4
4.3
33.5
35.5
g/l
2.54
81
527
74
428
2.36
6.52
5.0
3.6
2.3
2.4
mmol/l
0.60
65
377
12
24
5.33
5.84
1.4
1.3
—
—
—
0
0
21
69
3.35
5.45
2.0
1.9
—
—
—
0
0
50
263
2.31
5.30
1.5
2.0
1.2
1.4
mg/l
0.26
45
209
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
14
35
4.29
5.29
2.3
2.4
0.3
0.4
u/ml
—
9
20
41
201
2.40
5.08
2.2
1.8
—
—
—
0
0
53
296
2.19
4.81
2.9
2.3
—
—
—
0
0
86
588
2.01
4.46
4.7
4.1
—
—
—
0
0
78
516
2.00
4.44
2.0
1.9
86.7
92.5
pmol/l
0.45
41
279
120
927
2.20
4.43
5.3
3.8
14.7
14.8
pmol/l
0.15
112
825
128
1030
2.24
4.03
12.4
7.7
86.1
79.6
u/l
0.56
123
967
43
243
2.05
3.68
3.2
3.3
2.5
2.5
mmol/l
0.20
38
214
30
147
2.28
3.66
2.1
1.7
—
—
—
0
0
7
9
8.07
3.59
1.3
1.3
—
—
—
0
0
29
143
2.26
3.49
2.0
1.7
—
—
—
0
0
12
37
3.43
3.42
1.8
2.9
219.6
204.1
%
0.27
12
37
136
1148
2.28
3.39
6.2
4.5
2.0
2.0
mu/l
0.00
128
1027
23
106
2.37
3.22
3.0
2.5
63.0
64.3
ml/min/173m2
—
9
42
19
80
2.56
3.20
1.6
1.3
—
—
—
0
0
18
74
2.62
3.18
3.4
3.0
124.4
128.3
g/l
0.22
18
74
9
20
4.70
3.16
1.4
1.2
—
—
—
0
0
12
39
3.25
3.16
1.5
2.6
97.1
84.8
%
1.00
12
39
42
250
1.92
3.07
3.8
3.5
57.5
152.9
ng/l
1.06
35
196
49
308
1.85
3.03
1.9
1.9
2.8
3.2
mg/l
0.66
41
271
56
368
1.81
3.00
3.2
2.8
7605.4
6907.3
umol/l
0.03
49
313
146
1288
2.63
2.98
28.0
14.5
29.2
22.4
mg/l
1.71
129
1036
26
140
2.02
2.50
13.3
7.7
2.0
1.1
mmol/l
0.73
20
110
6
12
5.15
2.42
1.2
1.8
—
—
—
0
0
29
169
1.88
2.23
4.2
2.4
26.6
23.5
%
0.35
29
148
31
185
1.84
2.22
1.5
1.5
—
—
—
0
0
9
30
3.12
2.18
1.8
1.4
—
—
—
0
0
9
30
3.12
2.18
1.3
1.2
—
—
—
0
0
5
11
4.65
1.95
1.0
1.1
—
—
—
0
0
138
1239
1.86
1.91
25.0
14.1
80.2
79.3
ml/min/173m2
0.16
122
1021
92
750
1.54
1.89
2.7
2.7
—
—
—
0
0
32
206
1.69
1.78
4.2
2.2
13.7
13.5
umol/l
0.02
32
185
102
858
1.53
1.76
4.0
3.1
75.1
51.3
u/l
1.16
94
813
5
13
3.93
1.73
1.2
1.4
—
—
—
0
0
111
953
1.55
1.72
5.4
4.0
14.3
11.5
mm/h
0.92
105
877
56
417
1.53
1.72
6.9
4.0
27.6
11.2
mg/mmol
0.56
39
262
11
50
2.29
1.61
1.2
2.2
—
—
—
0
0
128
1144
1.61
1.57
29.1
15.4
38.0
40.3
%
1.80
100
826
80
653
1.45
1.52
4.7
3.5
0.0
0.0
estimate
0.00
14
122
79
645
1.45
1.49
6.5
4.7
0.0
0.0
estimate
0.00
16
127
64
505
1.45
1.44
3.6
2.6
183.0
140.3
ug/l
0.80
59
461
34
237
1.55
1.38
1.7
1.6
1014.5
1211.9
nmol/l
0.61
22
183
78
646
1.41
1.31
4.5
3.5
0.0
0.0
estimate
0.00
16
130
5
18
2.83
1.29
1.2
1.1
—
—
—
0
0
5
19
2.68
1.22
1.0
1.2
—
—
—
0
0
6
26
2.36
1.20
1.3
1.3
—
—
—
0
0
12
65
1.92
1.17
3.9
2.5
2.4
1.3
%
0.81
12
65
7
30
2.39
1.14
1.1
1.3
—
—
—
0
0
8
40
2.05
1.14
2.0
1.7
—
—
—
0
0
8
40
2.05
1.14
1.9
2.7
—
—
—
0
0
133
1226
1.52
1.13
8.0
6.0
43.4
40.2
mmol/mol
1.87
126
1142
13
74
1.82
1.10
17.2
6.7
25.4
24.5
mmol/l
0.41
13
74
14
82
1.78
1.09
1.5
1.5
—
—
—
0
0
9
45
2.06
1.07
2.6
2.1
—
—
—
0
0
53
425
1.37
1.04
5.7
2.2
46.0
57.7
u/l
2.74
48
398
146
1381
1.70
1.02
31.1
17.1
84.4
81.3
umol/l
0.29
146
1381
21
143
1.54
0.96
6.9
3.5
—
—
—
0
0
6
29
2.11
0.90
1.0
1.1
—
—
—
0
0
27
197
1.45
0.90
1.3
1.2
33.1
39.9
iu/ml
—
7
59
49
400
1.33
0.84
2.5
3.4
2261.2
1310.2
ng/l
0.52
42
332
138
1304
1.44
0.79
5.3
5.2
2.7
2.7
mmol/l
0.26
129
1190
14
91
1.59
0.78
1.6
1.6
—
—
—
0
0
6
106
0.55
0.75
1.8
1.7
—
—
—
0
0
5
24
2.12
0.75
1.8
1.5
—
—
—
0
0
5
24
2.12
0.75
2.0
2.0
—
—
—
0
0
5
24
2.12
0.75
1.8
1.5
—
—
—
0
0
5
26
1.95
0.71
1.0
1.2
—
—
—
0
0
61
525
1.26
0.69
4.3
3.9
32.5
52.6
ng/l
0.76
47
378
5
27
1.88
0.69
1.4
1.5
—
—
—
0
0
5
27
1.88
0.69
1.2
1.3
—
—
—
0
0
5
29
1.75
0.64
2.0
2.0
—
—
—
0
0
6
35
1.74
0.58
1.8
1.5
—
—
—
0
0
6
36
1.69
0.57
1.8
1.6
—
—
—
0
0
133
1270
1.29
0.52
4.5
4.7
1.3
1.4
mmol/l
2.57
124
1160
43
370
1.22
0.48
2.5
3.1
0.8
0.8
ug/l
0.06
32
240
133
1274
1.27
0.47
4.6
4.7
4.5
4.6
mmol/l
0.71
124
1175
131
1255
1.25
0.45
5.4
4.7
6.3
6.0
mmol/l
1.05
125
1141
129
1234
1.24
0.45
4.1
4.2
1.3
1.3
mmol/l
0.35
117
1128
5
32
1.58
0.42
1.4
1.5
—
—
—
0
0
5
32
1.58
0.42
1.6
1.3
—
—
—
0
0
0
19
0.00
0.39
0.0
1.2
—
7.4
—
0
12
5
36
1.40
0.38
1.6
1.3
—
2.5
—
0
10
41
360
1.19
0.37
1.6
1.7
1.5
1.3
mmol/l
0.85
36
301
39
347
1.16
0.31
5.7
3.7
0.0
0.0
estimate
0.00
14
123
5
39
1.29
0.23
2.4
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
2.9
—
13.8
—
0
10
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
10
82
1.23
0.17
1.8
1.5
—
—
—
0
0
5
45
1.11
0.10
3.6
1.8
—
—
—
0
0
6
57
1.05
0.08
1.3
1.4
—
—
—
0
0
18
166
1.10
0.08
9.7
7.6
—
—
—
0
0
52
507
1.04
0.04
5.7
3.7
—
—
—
0
0
64
629
1.03
0.03
4.3
5.1
2.0
2.8
ug/l
0.83
58
567
13
137
0.94
0.01
1.5
1.4
—
—
—
0
0
51
506
1.01
0.00
4.1
4.6
26.1
21.2
%
0.97
26
249
27
275
0.98
0.00
1.3
1.2
1.1
0.7
u/ml
—
6
79
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
6
60
1.00
0.00
1.2
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
4.4
—
—
—
0
0
0
5
0.00
0.00
0.0
3.4
—
67.4
—
0
5
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
4.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
10.3
—
0
5
Mortality – FinRegistry
↥Association
Association between endpoint CD2_BENIGN_HYPOPHARYNX and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_HYPOPHARYNX | 1.911 [1.25, 2.93] | 0.003 |
| Birth year | 0.988 [0.98, 1.0] | 0.006 |
During the follow-up period (1.1.1998 — 31.12.2019), 51 out of 188 females with CD2_BENIGN_HYPOPHARYNX died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_HYPOPHARYNX | 2.396 [1.56, 3.67] | < 0.001 |
| Birth year | 0.991 [0.98, 1.0] | 0.073 |
During the follow-up period (1.1.1998 — 31.12.2019), 104 out of 275 males with CD2_BENIGN_HYPOPHARYNX died.
Mortality risk
Mortality risk for people of age
years, who have CD2_BENIGN_HYPOPHARYNX.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.142% | 0.394% |
| 5 | 0.951% | 2.999% |
| 10 | 2.338% | 8.24% |
| 15 | 4.195% | 14.837% |
| 20 | 6.865% | 24.105% |
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_HYPOPHARYNX – Benign neoplasm: Hypopharynx
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data